Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 13/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23762506 | 0.91 | ENPP1 (0.62) | ENPP1AURKAACHEBACE1 | |
| SCHEMBL30117253 | 0.91 | ENPP1 (0.62) | ENPP1AURKAACHEBACE1 | |
| SCHEMBL25656098 | 0.88 | ENPP1 (0.50) | ENPP1SIRT2SIRT1SIRT3AURKA | |
| SCHEMBL25656114 | 0.86 | ENPP1 (0.67) | ENPP1LMNASMN1; SMN2NPSR1GLA | |
| SCHEMBL30117297 | 0.85 | ENPP1 (0.66) | ENPP1AURKAACHEBACE1 | |
| SCHEMBL23762283 | 0.85 | ENPP1 (0.66) | ENPP1AURKAACHEBACE1 | |
| SCHEMBL23726143 | 0.82 | ENPP1 (0.67) | ENPP1AURKAACHEBACE1 | |
| SCHEMBL23762311 | 0.81 | ENPP1 (0.60) | ENPP1AURKAACHEBACE1 | |
| SCHEMBL30117246 | 0.81 | ENPP1 (0.60) | ENPP1AURKAACHEBACE1 | |
| SCHEMBL25656111 | 0.80 | ENPP1 (0.64) | ENPP1LMNASIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PPA1 | ENPP1 1/4885LMNA 3401/4885SIRT2 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.